mAbxience |

Edmund
Carey

Edmund Carey is Global Head Quality and Compliance for Insud Pharma, responsible for all aspects of the quality and pharmacovigilance organizations across the business. Possessing over 20 years of experience in highly regulated pharmaceutical and biotechnology markets, with significant international experience living in Europe, India and Canada, Edmund is an experienced Quality Executive with a track record of building a culture of quality, executing transformational change, driving improvement and leading operations through great and difficult moments.

Prior to joining Insud Pharma, Edmund spent seven years at Apotex, Canada’s largest pharmaceutical company, in increasingly more responsible roles. He served as Vice President Quality and Compliance where he modernized quality in order to build a sustainable culture of quality across all aspects of the organization. Prior to that appointment, Edmund was Global Director, Quality Compliance where he was instrumental in establishing the global quality system, navigating difficult moments and drove enhancement of the industrial plants to assure regulatory conformance.

Prior to Apotex, Edmund spent ten years in increasingly more responsible roles at Biovail, a publically traded pharmaceutical company that used its patented controlled-release technology to improve upon drugs already approved by Health Authorities. He was Director, Global Quality Systems where he established programs to measure, monitor and improve the quality and compliance of the operations and business units, to standarize practices and assure regulatory conformance. Edmund also lead the global audit program and was the key liason with Health Authorities globally.

He holds a Bachelor of Science degree in Biology (Genetics) from the University of Western Ontario (London, Canada) and holds a Postgraduate Diploma in Pharmaceutical Quality Assurance from the Toronto Institute of Pharmaceutical Technology (Toronto, Canada). Edmund is a Canadian national, currently based in Spain.